MedTrace Logo

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

NCT04572542 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2020-10-01

No results posted yet for this study

Summary

To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate and nab-paclitaxel .

Conditions

  • Locally Advanced or Metastatic Gastric Adenocarcinoma

Interventions

DRUG

Camrelizumab

Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg

DRUG

Apatinib Mesylate

Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday

DRUG

nab-paclitaxel

nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2

Sponsors & Collaborators

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-06-01
Completion
2022-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04572542 on ClinicalTrials.gov